SHATTUCK LABS INC

STTKNASDAQ

🏆 #2446 by market capEarnings Nov 5US Equity

$7.75▲ $0.62 (+7.94%)

Live

1h▲ 5.5%

24h▲ 7.9%

7d▲ 5.2%

14d▲ 14.8%

30d▲ 20.7%

1y▲ 932.9%

🏦Market Cap

$700M

Small Cap

📈Revenue Growth (YoY)

-78.3%

Declining

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

645.3x

Expensive

Otter Score

Weak

Trading Snapshot

Day Range: $7.70 – $7.79
52-Week Range: $0.71 – $8.33
Volume: $2.49B
Avg Volume: $2.72B
Shares Outstanding: 90.4M
Next Earnings: Oct 23, 2026

Fundamentals Snapshot

Annual Revenue: $1M
Last Q Revenue: $227,341
P/E Ratio: —
P/S Ratio: 645.3x
EPS (TTM): $-0.64
Dividend Yield: —

Why Investors Own STTK

✓High-growth profile — revenue up +25.4% YoY with expanding US Equity exposure.
✓Healthy economics — 39% gross margin and 5% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$1M▲ +21.4% YoY

Gross Margin (TTM)

39.3%▲ +0.8% YoY

Operating Income (TTM)

$353,000▲ +21.4% YoY

Free Cash Flow (TTM)

$47,000▲ +21.4% YoY

About SHATTUCK LABS INC

Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.

🦦